NASDAQ:CYAN

Cyanotech Competitors

$3.14
+0.05 (+1.62 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.06
Now: $3.14
$3.14
50-Day Range
$3.09
MA: $3.57
$4.14
52-Week Range
$2.02
Now: $3.14
$6.29
Volume34,892 shs
Average Volume253,480 shs
Market Capitalization$19.14 million
P/E Ratio31.40
Dividend YieldN/A
Beta0.4

Competitors

Cyanotech (NASDAQ:CYAN) Vs. CGC, APHA, CRON, TLRY, USNA, and ACB

Should you be buying CYAN stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Cyanotech, including Canopy Growth (CGC), Aphria (APHA), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), and Aurora Cannabis (ACB).

Canopy Growth (NASDAQ:CGC) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Earnings and Valuation

This table compares Canopy Growth and Cyanotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million35.73$-993,370,000.00$1.3221.06
Cyanotech$31.90 million0.60$390,000.00N/AN/A

Cyanotech has lower revenue, but higher earnings than Canopy Growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Canopy Growth and Cyanotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth510211.94
Cyanotech0000N/A

Canopy Growth presently has a consensus price target of $35.6778, suggesting a potential upside of 28.34%. Given Canopy Growth's higher probable upside, equities research analysts clearly believe Canopy Growth is more favorable than Cyanotech.

Volatility and Risk

Canopy Growth has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Canopy Growth and Cyanotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
Cyanotech1.82%3.67%1.80%

Insider and Institutional Ownership

10.2% of Canopy Growth shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 0.3% of Canopy Growth shares are owned by insiders. Comparatively, 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cyanotech beats Canopy Growth on 7 of the 13 factors compared between the two stocks.

Aphria (NASDAQ:APHA) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Volatility and Risk

Aphria has a beta of 2.67, indicating that its share price is 167% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Earnings and Valuation

This table compares Aphria and Cyanotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67
Cyanotech$31.90 million0.60$390,000.00N/AN/A

Cyanotech has lower revenue, but higher earnings than Aphria.

Insider and Institutional Ownership

10.3% of Aphria shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aphria and Cyanotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aphria05302.38
Cyanotech0000N/A

Aphria presently has a consensus price target of $22.00, suggesting a potential upside of 55.59%. Given Aphria's higher probable upside, equities research analysts clearly believe Aphria is more favorable than Cyanotech.

Profitability

This table compares Aphria and Cyanotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aphria-36.10%-2.30%-1.66%
Cyanotech1.82%3.67%1.80%

Summary

Cyanotech beats Aphria on 7 of the 12 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

Cronos Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cronos Group and Cyanotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million117.46$1.17 billion$0.6712.48
Cyanotech$31.90 million0.60$390,000.00N/AN/A

Cronos Group has higher earnings, but lower revenue than Cyanotech.

Insider & Institutional Ownership

11.8% of Cronos Group shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by insiders. Comparatively, 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Cronos Group and Cyanotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group24101.86
Cyanotech0000N/A

Cronos Group presently has a consensus price target of $8.75, suggesting a potential upside of 4.67%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Cyanotech.

Profitability

This table compares Cronos Group and Cyanotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Cyanotech1.82%3.67%1.80%

Summary

Cronos Group beats Cyanotech on 8 of the 12 factors compared between the two stocks.

Tilray (NASDAQ:TLRY) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

Tilray has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Valuation and Earnings

This table compares Tilray and Cyanotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray$166.98 million17.69$-321,170,000.00($1.69)-10.18
Cyanotech$31.90 million0.60$390,000.00N/AN/A

Cyanotech has lower revenue, but higher earnings than Tilray.

Insider & Institutional Ownership

12.6% of Tilray shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 16.8% of Tilray shares are owned by insiders. Comparatively, 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Tilray and Cyanotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tilray19001.90
Cyanotech0000N/A

Tilray presently has a consensus price target of $18.3078, suggesting a potential upside of 6.44%. Given Tilray's higher probable upside, analysts plainly believe Tilray is more favorable than Cyanotech.

Profitability

This table compares Tilray and Cyanotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tilray-242.60%-92.70%-20.70%
Cyanotech1.82%3.67%1.80%

Summary

Cyanotech beats Tilray on 6 of the 11 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Valuation and Earnings

This table compares USANA Health Sciences and Cyanotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion1.92$100.53 million$4.4122.42
Cyanotech$31.90 million0.60$390,000.00N/AN/A

USANA Health Sciences has higher revenue and earnings than Cyanotech.

Insider & Institutional Ownership

54.1% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by insiders. Comparatively, 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for USANA Health Sciences and Cyanotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Cyanotech0000N/A

USANA Health Sciences presently has a consensus price target of $126.00, suggesting a potential upside of 27.41%. Given USANA Health Sciences' higher probable upside, analysts plainly believe USANA Health Sciences is more favorable than Cyanotech.

Profitability

This table compares USANA Health Sciences and Cyanotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Cyanotech1.82%3.67%1.80%

Summary

USANA Health Sciences beats Cyanotech on 11 of the 12 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and Cyanotech (NASDAQ:CYAN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Aurora Cannabis and Cyanotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis69001.60
Cyanotech0000N/A

Aurora Cannabis presently has a consensus price target of $10.9264, suggesting a potential upside of 38.66%. Given Aurora Cannabis' higher probable upside, analysts plainly believe Aurora Cannabis is more favorable than Cyanotech.

Volatility and Risk

Aurora Cannabis has a beta of 3.44, indicating that its stock price is 244% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Insider & Institutional Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Aurora Cannabis and Cyanotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
Cyanotech1.82%3.67%1.80%

Valuation and Earnings

This table compares Aurora Cannabis and Cyanotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million7.50$-2,468,190,000.00($2.86)-2.76
Cyanotech$31.90 million0.60$390,000.00N/AN/A

Cyanotech has lower revenue, but higher earnings than Aurora Cannabis.

Summary

Cyanotech beats Aurora Cannabis on 6 of the 11 factors compared between the two stocks.


Cyanotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
CGC
Canopy Growth
1.0$27.80+1.4%$10.62 billion$297.34 million-8.32News Coverage
Aphria logo
APHA
Aphria
1.6$14.14+3.9%$4.48 billion$405.96 million-23.97Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
Cronos Group logo
CRON
Cronos Group
0.8$8.36+2.6%$3.01 billion$25.64 million34.83Analyst Downgrade
Tilray logo
TLRY
Tilray
1.0$17.20+1.5%$2.95 billion$166.98 million-3.79News Coverage
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$98.89+2.6%$2.04 billion$1.06 billion18.31Analyst Downgrade
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$7.88+1.1%$1.56 billion$207.89 million-0.32Analyst Downgrade
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.85+1.2%$1.41 billion$75.86 million-0.33Analyst Upgrade
Gap Up
HEXO logo
HEXO
HEXO
1.1$5.52+3.3%$676.12 million$60.46 million-1.13Gap Up
ChromaDex logo
CDXC
ChromaDex
1.3$8.20+4.0%$547.41 million$46.29 million-21.58
MediWound logo
MDWD
MediWound
1.4$5.04+2.0%$137.27 million$31.79 million-12.60Decrease in Short Interest
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$18.20+6.3%$115.72 million$118.88 million227.53High Trading Volume
Increase in Short Interest
Gap Up
HAPP
Happiness Biotech Group
0.6$1.84+0.5%$47.53 million$65.06 million0.00Increase in Short Interest
News Coverage
Mannatech logo
MTEX
Mannatech
1.3$19.13+2.4%$39.58 million$157.73 million5.89Gap Down
FSD Pharma logo
HUGE
FSD Pharma
0.3$1.56+1.9%$29.89 million$190,000.00-0.35Increase in Short Interest
News Coverage
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.